mRNA SARS-CoV-2疫苗后新发或恶化的甲状腺眼病:2例报告及文献综述
本文报告2例mRNA SARS-CoV-2疫苗接种后甲状腺眼病(TED)激活病例,并结合文献检索到的8例共10例进行分析。其中4例为新发TED,6例为既往稳定TED显著恶化;7例接受替妥木单抗治疗并获得良好反应。作者认为多数病例见于基础自身免疫性甲状腺疾病患者,需进一步研究机制、危险因素、预防和治疗。
要点
- mRNA SARS-CoV-2疫苗接种后新发或恶化TED可发生,多数见于基础自身免疫性甲状腺疾病患者。
- 10例中4例新发TED、6例既往稳定TED显著恶化;2例进展为甲状腺功能障碍性视神经病变。
- 7例接受替妥木单抗治疗并获得良好反应。
核心结论
- mRNA SARS-CoV-2疫苗接种后新诊断或恶化的TED可以发生,多数病例见于有基础自身免疫性甲状腺疾病的患者。
- 本文报告旨在提高对该潜在并发症的认识,以促进mRNA SARS-CoV-2疫苗相关TED的早期识别和及时管理。
- 需要进一步研究以探索mRNA SARS-CoV-2疫苗接种后TED的机制、危险因素、预防和治疗。
研究设计与样本
- 本文报告2例mRNA SARS-CoV-2疫苗接种后TED激活病例,并进行文献综述。
- 文献检索至2022年6月,共发现8例 adicionales 报告的与SARS-CoV-2疫苗接种相关的TED病例,合计10例。
- 2例本文病例中,1例为Graves病患者TED恶化,1例为Hashimoto甲状腺功能减退病史患者新发活动性TED并进展为甲状腺功能障碍性视神经病变。
主要发现
- 10例报告的SARS-CoV-2疫苗接种后TED病例中,4例为新发TED,6例为既往稳定TED显著恶化。
- 6例有已知Graves病,2例有Hashimoto甲状腺炎。
- 2例进展为甲状腺功能障碍性视神经病变,6例为中度/重度活动性疾病,2例为轻度疾病且不需要治疗。
- 7例TED病例接受替妥木单抗治疗并获得良好反应,其中2例先前对初始泼尼松或甲泼尼龙及托珠单抗治疗反应有限。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Occurrence of Graves' disease (GD) has been reported following SARS-CoV-2 vaccine administration, but little is known about thyroid eye disease (TED) after SARS-CoV-2 vaccination. OBJECTIVE: We describe 2 cases of TED activation following mRNA SARS-CoV-2 vaccination and review additional cases reported in the literature. METHODS: We report 2 cases of TED activation following SARS-CoV-2 vaccination: 1 case of TED worsening in a patient with GD, and 1 of de novo active TED progressing to dysthyroid optic neuropathy in a patient with a history of Hashimoto hypothyroidism. Our literature search revealed 8 additional reported TED cases associated with SARS-CoV-2 vaccination until June 2022. We review the characteristics, duration, and management of TED following SARS-CoV-2 vaccination in these cases. RESULTS: Of all 10 reported TED cases following SARS-CoV-2 vaccination, 4 developed new-onset TED and 6 previously stable TED cases experienced significant deterioration. Six patients had known GD and 2 patients had Hashimoto thyroiditis. Two cases progressed to dysthyroid optic neuropathy, 6 had moderate/severe active disease, and 2 had mild disease that did not require treatment. Seven TED cases received teprotumumab and had a favorable response, 2 of whom had prior limited response to initial prednisone or methylprednisolone and tocilizumab therapy. CONCLUSION: New diagnosis or deterioration of TED after mRNA SARS-CoV-2 vaccination can occur, with most cases described in patients with underlying autoimmune thyroid disease. Our report raises awareness to this potential complication to promote early recognition and prompt management of TED associated with mRNA SARS-CoV-2 vaccines. Further studies are needed to explore the mechanism, risk factors, prevention, and treatment of TED following mRNA SARS-CoV-2 vaccination.
引用
- Mohamed A, Tzoulis P, Kossler AL, et al. New Onset or Deterioration of Thyroid Eye Disease After mRNA SARS-CoV-2 Vaccines: Report of 2 Cases and Literature Review. J Clin Endocrinol Metab. 2023. PMID: 36251747. doi:10.1210/clinem/dgac606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。